U.S., June 17 -- ClinicalTrials.gov registry received information related to the study (NCT07649928) titled 'A Study of Dose Escalation of ES502 in Patients With Advanced Pancreatic Cancer' on June 05.
Brief Summary: ESSIGHT-HJG-ES502-01 is a dose-escalation study of ES502 in patients with advanced pancreatic cancer. The study will enroll patients with advanced, RAS G12V positive pancreatic cancer who have no effective treatment options available (HLA genotyping required).
Study Start Date: May 18
Study Type: INTERVENTIONAL
Condition:
Pancreatic Cancer
Intervention:
DRUG: ES502 Injection
Bispecific soluble HLA-DP restricted RASG12V specific T-cell receptor fused to anti-CD3 with Fc
Recruitment Status: RECRUITING
Sponsor: Ruijin Ho...